2016
DOI: 10.1016/j.remn.2015.11.001
|View full text |Cite
|
Sign up to set email alerts
|

Mediastinal schwannoma mimicking lymph node metastasis from locally advanced breast cancer in a 18 F-FDG PET/CT study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 3 publications
0
3
0
Order By: Relevance
“…Mediastinal schwannomas can be misdiagnosed as lymph node metastasis [ 17 ]. The clinical distinction between mediastinal schwannoma and metastasis in cases where there is a history of cancer can be difficult, and requires surgical removal followed by histopathological analysis.…”
Section: Main Textmentioning
confidence: 99%
See 1 more Smart Citation
“…Mediastinal schwannomas can be misdiagnosed as lymph node metastasis [ 17 ]. The clinical distinction between mediastinal schwannoma and metastasis in cases where there is a history of cancer can be difficult, and requires surgical removal followed by histopathological analysis.…”
Section: Main Textmentioning
confidence: 99%
“…The location and composition obtained by means of imaging studies are critical to make a differential diagnosis. Even when using sophisticated studies, such a 18 F-fluorodeoxyglucose positron emission tomography and computed tomography ( 18 F-FDG PET/CT), mediastinal schwannomas can simulate metastases of breast cancer lymph nodes, as shown by Martinez-Esteve et al [ 17 ]. Similarly, we found a patient with a clinical history of stage IIB breast cancer during follow-up, which showed a mediastinal mass on a chest X-ray that was initially thought to be a recurrence of the disease.…”
Section: Main Textmentioning
confidence: 99%
“…For example Martinez-Esteve et al ( 1 ) have reported the case of a patient with a locally advanced HER2 overexpressed breast tumor treated by chemotherapy and Trastuzumab showing a hypermetabolic retro-tracheal lymphadenopathy [15 × 17 mm and standardized uptake value (SUVmax) 4.5]. On the 18F-FDG PET-CT intermediate therapeutic assessment, there was a complete metabolic response except for the retro tracheal lymphadenopathy.…”
Section: Introductionmentioning
confidence: 99%